Sign In
Buy VTGN
$0.560
-0.0199 (-3.43%)
At Close: Jun 03, 2026
Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027
01:28pm, Tuesday, 09'th Apr 2024
Finding possibilities in investing frequently depends on finding companies attached to rapid expansion and value generation. Examine these three prospects, each selling at less than $10 per share and
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
08:30am, Tuesday, 09'th Apr 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapi
Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027
10:00am, Sunday, 31'st Mar 2024
Finding undiscovered opportunities can result in significant profits in an investment landscape frequently controlled by well-known giants. These three obscure stocks have the potential to provide imp
Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish
09:01pm, Wednesday, 20'th Mar 2024
Vistagen Therapeutics has proprietary platform technologies for developing innovative drugs for mental health disorders. The company's pipeline includes candidates for social anxiety disorder, major d
Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments
03:07am, Sunday, 17'th Mar 2024
VistaGen Therapeutics is developing CNS drugs for anxiety, depression, and other disorders, with Fasedienol in phase 3 clinical trials. Fasedienol has advantages as a non-systemic, low-abuse anxiolyti
This overlooked corner of women's health could be a $350 billion market opportunity
02:33pm, Friday, 15'th Mar 2024
Menopause is among the female health conditions with the highest unmet need and has 'enormous potential for innovative treatments,' according to McKinsey.
Vistagen to Present at Stifel 2024 Virtual CNS Days
08:30am, Monday, 11'th Mar 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals a
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
08:30am, Wednesday, 28'th Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals a
Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?
10:56am, Wednesday, 21'st Feb 2024
The mean of analysts' price targets for VistaGen Therapeutics, Inc. (VTGN) points to a 160% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agree
3 Revolutionary Biotech Stocks Poised for 10X Surge
12:24pm, Monday, 19'th Feb 2024
Investing in high-potential biotech stocks should catapult your portfolio to new heights. Picture this: a global biotech market valued at a whopping $1.55 trillion in 2023 is set to catapult to $3.08
Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Call Transcript
06:34pm, Tuesday, 13'th Feb 2024
Vistagen Therapeutics, Inc. (VTGN) Q3 2024 Earnings Call Transcript
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
04:20pm, Tuesday, 13'th Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapi
3 Penny Stocks to Buy for the Next Bull Run: February 2024
07:38am, Wednesday, 07'th Feb 2024
Entering 2024, a shift toward optimism emerges in the market, with eased monetary policies potentially opening doors for penny stocks to rebound. Savvy investors, drawn to overlooked opportunities, ma
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
08:30am, Tuesday, 06'th Feb 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapi
3 Penny Stocks to Turn $999 Into $1 Million: January 2024
09:04am, Friday, 26'th Jan 2024
Despite the recent economic deceleration, positive factors like a tight labor market and strong consumer spending support a resilient U.S. economy. Goldman Sachs predicts increased state and local gov
